Short answer
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $51M (up 8.5% year over year) with net income of −$12M.
Q2 2026 key financials · XBRL
- Revenue
- $51M
- +8.5% YoY · −21.9% QoQ
- Net income
- −$12M
- +68.6% YoY · −232.6% QoQ
- Operating margin
- -29.3%
- Gross margin
- 40.1%
- EPS (diluted)
- −$0.09
- +66.7% YoY · −350.0% QoQ
Source: XBRL data from the MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Q2 2026 10-Q on SEC EDGAR. USD.
MARAVAI LIFESCIENCES HOLDINGS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $51.4M, up from $47.4M YoY
- TriLink revenue $34.7M vs $31.1M, strongest segment
- Cygnus revenue $16.8M vs $16.3M, weakest segment growth
- SG&A $32.1M vs $38.7M; R&D $3.7M vs $4.9M
- No second-quarter CleanCap revenue; no further high-volume orders expected in 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- No newly added risk factor identified for the quarter
- Regulatory and compliance risks remain those carried forward from the 2025 Form 10-K
- No director or officer adopted or terminated Rule 10b5-1 arrangements during three months ended June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MARAVAI LIFESCIENCES HOLDINGS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.